Fornes Abby, Huff Jamie, Pritchard Roger Iain, Godfrey Miranda
Bernard J. Dunn School of Pharmacy, Shenandoah University, Fairfax, VA, USA.
Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA, USA.
J Pharm Technol. 2022 Aug;38(4):239-246. doi: 10.1177/87551225221092681. Epub 2022 May 13.
To review the efficacy, safety, and role of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide for chronic weight management. A literature search of PubMed/MEDLINE and Google Scholar was performed using the search terms: semaglutide 2.4, weight, and obesity. Ongoing studies of semaglutide were identified utilizing clinicaltrials.gov. All English-language articles evaluating the efficacy and safety of semaglutide 2.4 mg for weight management in humans were included. Once-weekly injectable semaglutide 2.4 mg is indicated as an adjunct to a reduced-calorie diet and increased exercise for chronic weight management in adults with a body mass index (BMI) ≥30 kg/m or ≥27 kg/m with at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or dyslipidemia. Semaglutide 2.4 mg has consistently demonstrated clinically significant weight loss across all phase 3 STEP (semaglutide treatment effect in people with obesity) trials, and long-term efficacy and safety have been confirmed for up to 2 years. Gastrointestinal side effects were the most frequently reported side effects, including nausea, vomiting, constipation, and diarrhea. Safety data for semaglutide 2.4 mg were consistent with that reported previously for the GLP-1 receptor agonist class. Semaglutide 2.4 mg is a highly efficacious agent for weight management, with a safety profile similar to that of other GLP-1 receptor agonists. It is a feasible option for chronic weight management, with data for up to 2 years. It is currently the only once-weekly weight loss medication, although cost may limit its utilization.
回顾胰高血糖素样肽-1（GLP-1）受体激动剂司美格鲁肽在慢性体重管理中的疗效、安全性及作用。使用搜索词“司美格鲁肽2.4、体重和肥胖症”在PubMed/MEDLINE和谷歌学术上进行文献检索。利用clinicaltrials.gov识别正在进行的司美格鲁肽研究。纳入所有评估2.4毫克司美格鲁肽对人类体重管理疗效和安全性的英文文章。每周一次注射2.4毫克司美格鲁肽被指定作为低热量饮食和增加运动的辅助手段，用于体重指数（BMI）≥30kg/m²或≥27kg/m²且至少有一种与体重相关合并症（如高血压、2型糖尿病或血脂异常）的成年人的慢性体重管理。在所有3期STEP（司美格鲁肽对肥胖人群的治疗效果）试验中，2.4毫克司美格鲁肽始终显示出具有临床意义的体重减轻，并且已证实长达2年的长期疗效和安全性。胃肠道副作用是最常报告的副作用，包括恶心、呕吐、便秘和腹泻。2.4毫克司美格鲁肽的安全性数据与先前报道的GLP-1受体激动剂类药物的数据一致。2.4毫克司美格鲁肽是一种用于体重管理的高效药物，其安全性与其他GLP-1受体激动剂相似。它是慢性体重管理的一个可行选择，有长达2年的数据。它是目前唯一一种每周注射一次的减肥药物，尽管成本可能会限制其使用。
